Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance

Journal of Substance Abuse Treatment

Volumn 35, Issue 1, 2008, Pages 78-86

  Willner Reid, Jessica ^a   Belendiuk, Katherine A ^b   Epstein, David H ^a   Schmittner, John ^a   Preston, Kenzie L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Hepatitis C; Injection drug use; Methadone maintenance; Risk behaviors; Substance abuse

Indexed keywords

METHADONE;

ADULT; AGED; ARTICLE; BEHAVIOR; BLOOD DISEASE; CLINICAL PRACTICE; CONDOM; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG USE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INJECTION; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; NEEDLE; PRIORITY JOURNAL; PUBLIC HEALTH; RATING SCALE; RISK; SEX; STATISTICAL SIGNIFICANCE;

ADULT; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; METHADONE; QUESTIONNAIRES; RISK-TAKING; SEXUAL BEHAVIOR; SUBSTANCE-RELATED DISORDERS;

EID: 44349140004     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2007.08.011     Document Type: Article

References (48)

1. Alter M.J. Epidemiology of hepatitis C in the West. Seminars in Liver Disease 15 (1995) 5-14
2. Alter M.J., Kruszon-Moran M.D., Nainan O.V., et al. The prevalence of hepatitis C virus infections in the United States, 1988 through 1994. New England Journal of Medicine 341 (1999) 556-562
3. Baker A., Heather N., Wodak A., Dixon J., and Holt P. Evaluation of a cognitive-behavioral intervention for HIV prevention among injecting drug users. AIDS 7 (1993) 247-256
4. Baron R.M., and Kenny D.A. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic and statistical considerations. Journal of Personality and Social Psychology 51 (1986) 1173-1182
5. Bollepalli S., Mathieson K., Bay C., Hillier A., Post J., Van Thiel D.H., et al. Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients. Sexually Transmitted Diseases 33 (2006) 000
6. Centers for Disease Control and Prevention. National hepatitis C prevention strategy for the prevention and control of hepatitis C virus infection and consequences. Online at:. http://www.cdc.gov/ncidod/diseases/hepatitis/c/plan/HCV_infection.htm (Accessed October 19, 2006)
7. Cohen D.E., Russell C.J., Golub S.A., and Mayer K.H. Prevalence of hepatitis C virus infection among men who have sex with men at a Boston community health center and its association with markers of high-risk behavior. AIDS Patient Care and STDs 20 (2006) 557-564
8. Crofts N., Hopper J.L., Bowden D.S., Breschkin A.M., Milner R., and Locarnini S.A. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Medical Journal of Australia 159 (1993) 237-241
9. Crofts N., Nigro L., Oman K., Stevenson E., and Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 92 (1997) 999-1005
10. Darke S., Hall W., Heather N., Ward J., and Wodak A. The reliability and validity of a scale to measure HIV risk-taking among intravenous drug users. AIDS 5 (1991) 181-185
11. Epstein D.H., Schmittner J., Schroeder J.R., and Preston K.L. Promoting simultaneous abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. 65th Annual Scientific Meeting of the College on Problems of Drug Dependence: Bal Harbour, FL (2003)
12. Epstein D.H., Schmittner J., Schroeder J.R., and Preston K.L. Comparison of two schedules of lottery-based abstinence reinforcement in polydrug users in methadone maintenance therapy. European Behavioural Pharmacology Society: Alicante, Spain (2005)
13. Fabris P., Tositti G., Giordani M.T., Baldo V., Grasso A., Pignattari E., et al. Assessing patients' understanding of hepatitis C virus infection and its impact on their lifestyle. Alimentary Pharmacology and Therapeutics 23 (2006) 1161-1170
14. Gottheil E., Lundy A., Weinstein S.P., and Sterling R.C. Does intensive outpatient cocaine treatment reduce AIDS risky behaviors?. Journal of Addictive Diseases 17 (1998) 61-69
15. Hagan F. Hepatitis C virus transmission dynamics in injection drug users. Substance Use & Misuse 33 (1998) 1197-1212
16. Hagan H., Campbell J., Thiede H., Strathdee S., Ouellet L., Kapadia F., et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports 121 (2006) 710-719
17. Howe C.H., Fuller C.M., Ompad D.C., Galea S., Koblin B., Thomas D., et al. Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug and Alcohol Dependence 79 (2005) 389-395
18. Janssen R.S., Holtgrave D.R., Valdiserri R.O., Sheperd M., Gayle H.D., and DeCock K.M. The serostatus approach to fighting the HIV epidemic: Prevention strategies for infected individuals. American Journal of Public Health 91 (2001) 1019-1024
19. Koblin B.A., Factor S.H., Wu Y., and Vlahov D. Hepatitis C virus infection among noninjecting drug users in New York City. Journal of Medical Virology 70 (2003) 387-390
20. Kwiatkowski C.F., and Booth R.E. Methadone maintenance as HIV risk reduction with street-recruited injecting drug users. Journal of Acquired Immune Deficiency Syndromes 26 (2001) 483-489
21. Kwiatkowski C.F., Fortuin Corsi K., and Booth R.E. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 97 (2002) 1289-1294
22. Maher L., Jalaudin B., Chant K.G., Jayasuriya R., Sladden T., Kaldor J.M., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 101 (2006) 1499-1508
23. Mathei C., Shkedy Z., Denis B., Kabali C., Aerts M., Molenberghs G., et al. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. Journal of Viral Hepatitis 13 (2006) 560-570
24. Mansell C.J., and Locarnini S.A. Epidemiology of hepatitis C in the East. Seminars in Liver Disease 15 (1995) 15-32
25. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., et al. New data from the Addiction Severity Index. Reliability and validity in three centers. Journal of Nervous and Mental Disease 173 (1985) 412-423
26. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes 6 (1993) 1049-1056
27. Miller M., Mella I., Moi H., and Eskild A. HIV and Hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway. Journal of Acquired Immune Deficiency Syndromes 33 (2003) 373-379
28. Millson P., Challacombe L., Villeneuve P.J., Strike C.J., Fischer B., Myers T., et al. Reduction in injection-related risk after 6 months in a low-threshold methadone treatment program. AIDS Education and Prevention 19 (2007) 124-136
29. Moss A.R., Vranizan K., Gorter R., Bacchetti P., Watters J., and Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 8 (1994) 223-231
30. Ompad D.C., Fuller C.M., Vlahov D., Thomas D., and Strathdee S.A. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 35 (2002) 783-788
31. Patrick D.M., Tyndall M.W., Cornelisse P.G., Li K., Sherlock C.H., Rekart M.L., et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canadian Medical Association Journal 165 (2001) 889-895
32. Quaglio G.L., Lugoboni F., Pajusco B., Sarti M., Talamini G., Mezzelani P., et al. Hepatitis C virus infection: Prevalence, predictor variables and prevention opportunities among drug users in Italy. Journal of Viral Hepatitis 10 (2003) 394-400
33. Rezza G., Sagliocca L., Zaccarelli M., Nespoli M., Siconolfi M., and Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scandinavian Journal of Infectious Diseases 28 (1996) 27-29
34. Robins L.N., Cottler L.B., Bucholz K.K., and Compton III W.M. The Diagnostic Interview Schedule, version IV (1995), Washington University, St. Louis, MO
35. Roy K., Hay G., Andragetti R., Taylor A., Goldberg D., and Wiessing L. Monitoring Hepatitis C virus infection among injecting drug users in the European Union: A review of the literature. Epidemiology and Infection 129 (2002) 577-585
36. SAS Institute Inc. SAS user's guide. Statistics. Version 6 ed. (1990), SAS Institute Inc, Cary, NC
37. Schroeder J.R., Epstein D.H., Umbricht A., and Preston K.L. Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addictive Behaviors 31 (2006) 868-879
38. Selvey L.A., Denton M., and Plant A.J. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: Factors influencing hepatitis C serostatus. Australian and New Zealand Journal of Public Health 21 (1997) 102-104
39. Sorensen J.L., and Copeland A.L. Drug abuse treatment as an HIV prevention strategy: A review. Drug and Alcohol Dependence 59 (2000) 17-31
40. Stark K., Müller R., Bienzle U., and Guggenmoos-Holzmann I. Methadone maintenance treatment and HIV risk-taking behavior among injecting drug users in Berlin. Journal of Epidemiology and Community Health 50 (1996) 534-537
41. Strathdee S.A., and Patterson T.L. Behavioral interventions for HIV positive and HCV positive drug users. AIDS and Behavior 10 (2006) 115-130
42. Thiede H., Hagan H., and Murrill C.S. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health: Bulletin of the New York Academy of Medicine 77 (2000) 331-345
43. Turner J.M., Rider A.T., Imrie J., Copas A.J., Edwards S.G., Dodds J.P., et al. Behavioural predictors of subsequent hepatitis C diagnosis in a UK clinic sample of HIV positive men who have sex with men. Sexually Transmitted Infections 82 (2006) 298-300
44. Van Beek I., Dwyer R., Dore G.J., Luo K., and Kaldor J.M. Infection with HIV and Hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study. British Medical Journal 317 (1998) 433-437
45. Vidal-Trécan G., Coste J., Varescon-Pousson I., Christoforov B., and Boissonnas A. HCV status knowledge and risk behaviors amongst intravenous drug users. European Journal of Epidemiology 16 (2000) 439-445
46. Ward J., Mattick R.P., and Hall W. The effectiveness of methadone maintenance treatment 2: HIV and infectious hepatitis. In: Ward J., Mattick R.P., and Hall W. (Eds). Methadone maintenance treatment and other opioid replacement therapies (1998), Harwood Academic Publishers, Amsterdam 59-73
47. Weaver M.F., Cropsey K.L., and Fox S.A. HCV prevalence in methadone maintenance: Self-report versus serum test. American Journal of Health Behavior 29 (2005) 387-394
48. World Health Organization. Online at:. http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html (Accessed October 19, 2006)